Schedule 13G/A: FMR LLC Reports 11.5% Stake in Xenon Pharmaceuticals

Rhea-AI Filing Summary

Filing: Schedule 13G/A by FMR LLC and Abigail P. Johnson reporting beneficial ownership in XENON PHARMACEUTICALS INC (CUSIP 98420N105). The statement reflects an event date of 06/30/2025 and signature dated 08/05/2025.

Holdings: Aggregate beneficial ownership is 8,824,363 shares, representing 11.5% of the class. On the cover data FMR LLC reports sole voting power of 8,824,348, sole dispositive power of 8,824,363, and zero shared voting/dispositive power. Abigail P. Johnson is reported with sole dispositive power of 8,824,363 and no voting power shown. The filing states the securities were acquired and are held in the ordinary course of business and not to change or influence control of the issuer. Exhibit 99 and Exhibit 24 (power of attorney) are referenced.

Positive

• FMR LLC and Abigail P. Johnson beneficially own 8,824,363 shares (11.5%)
• Filing certifies securities were acquired and are held in the ordinary course and not to influence control
• Specific voting and dispositive power figures are disclosed on the cover page

Negative

• None.

Insights

Financial Analyst

TL;DR: FMR LLC and Abigail P. Johnson report a sizable 11.5% passive stake in XENE; holdings appear reported as held in the ordinary course.

The filing discloses 8,824,363 shares (11.5%) beneficially owned as of the 06/30/2025 event date, with FMR LLC showing near-parity sole voting and dispositive figures and Abigail P. Johnson listed with sole dispositive power but no voting power. Item 10 certifies the position was not acquired to influence control. For investors, this is material ownership disclosure but the filing explicitly characterizes the position as passive and ordinary-course, and no schedule 13D-level activist intent or additional transactions are disclosed in the document.

Corporate Governance Expert

TL;DR: A >5% stake is disclosed, but the filing affirms a passive posture and reports no shared control; governance implications appear limited per the statement.

The Schedule 13G/A lists FMR LLC and Abigail P. Johnson as reporting persons and documents specific voting/dispositive figures: FMR LLC sole voting 8,824,348, sole dispositive 8,824,363; Abigail P. Johnson sole dispositive 8,824,363, no voting power. The certification in Item 10 states holdings were not acquired to change or influence control. The filing references Exhibit 99 for the 13d-1(k)(1) agreement and a power of attorney (Exhibit 24) incorporated by reference, which are administrative items relevant to legal form but do not, in this document, indicate governance action.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

XENON PHARMACEUTICALS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

98420N105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 98420N105

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 8,824,348.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,824,363.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,824,363.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.5 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 98420N105

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 8,824,363.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

8,824,363.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

11.5 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: XENON PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 200-3650 Gilmore Way ,Burnaby,A1,CA,V5G 48W
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 98420N105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 8824363.00
(b)	Percent of class: 11.5 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 8824363.00
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of XENON PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of XENON PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	08/05/2025

Abigail P. Johnson

Signature:	Richard Bourgelas
Name/Title:	Duly authorized under Power of Attorney effective as of May 23, 2023, by and on behalf of Abigail P. Johnson*
Date:	08/05/2025

Comments accompanying signature: *This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on August 8, 2023, accession number: 0000315066-23-002397.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

How many XENE shares does FMR LLC report beneficially owning?

The filing reports 8,824,363 shares beneficially owned by FMR LLC (aggregate amount).

What percentage of XENON PHARMACEUTICALS (XENE) does this represent?

The reported position represents 11.5% of the outstanding common stock.

What voting and dispositive powers are reported for FMR LLC and Abigail P. Johnson?

FMR LLC reports sole voting power of 8,824,348 and sole dispositive power of 8,824,363; Abigail P. Johnson reports sole dispositive power of 8,824,363 and no voting power shown.

When is the event date and when was this Schedule 13G/A signed?

The event date is 06/30/2025 and the signature date on the filing is 08/05/2025.

Does the filing claim the position is intended to influence control of XENE?

No; Item 10 contains a certification that the securities were acquired and are held in the ordinary course of business and were not acquired to change or influence control of the issuer.